Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,590,000 shares, a decrease of 94.6% from the March 31st total of 47,720,000 shares. Based on an average daily trading volume, of 665,300 shares, the short-interest ratio is presently 3.9 days. Approximately 13.0% of the shares of the company are sold short.

Agenus Stock Performance

Agenus stock opened at $8.30 on Friday. The company has a market cap of $173.89 million, a P/E ratio of -0.58 and a beta of 1.26. Agenus has a one year low of $4.78 and a one year high of $42.60. The business has a fifty day moving average of $10.97 and a two-hundred day moving average of $13.79.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The company had revenue of $83.80 million for the quarter, compared to analysts’ expectations of $54.21 million. Sell-side analysts predict that Agenus will post -8.21 EPS for the current year.

Insider Activity

In related news, insider Garo H. Armen acquired 25,000 shares of Agenus stock in a transaction on Thursday, February 15th. The stock was purchased at an average cost of $13.00 per share, with a total value of $325,000.00. Following the purchase, the insider now directly owns 31,298 shares in the company, valued at $406,874. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Agenus

Institutional investors and hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. increased its holdings in Agenus by 3,008.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 2,232,064 shares in the last quarter. Braidwell LP increased its stake in shares of Agenus by 34.3% during the 3rd quarter. Braidwell LP now owns 6,307,030 shares of the biotechnology company’s stock worth $7,127,000 after purchasing an additional 1,609,100 shares in the last quarter. Pennant Investors LP acquired a new position in shares of Agenus during the 4th quarter worth approximately $389,000. Vanguard Group Inc. lifted its stake in Agenus by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 26,938,439 shares of the biotechnology company’s stock valued at $30,440,000 after buying an additional 432,202 shares in the last quarter. Finally, Caxton Associates LP grew its holdings in Agenus by 247.3% during the 3rd quarter. Caxton Associates LP now owns 390,234 shares of the biotechnology company’s stock valued at $441,000 after buying an additional 277,863 shares during the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

Analyst Ratings Changes

AGEN has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $160.00 target price on shares of Agenus in a research note on Thursday, March 14th. B. Riley reduced their price objective on shares of Agenus from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, March 18th. Finally, StockNews.com started coverage on Agenus in a report on Wednesday, April 17th. They issued a “hold” rating on the stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.